Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lafon

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|February 27, 1999
Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adultsP N Kumar, D E Sweet, J A McDowell, et al.
Clinical Therapeutics|December 1, 2001
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavirS Hetherington, S McGuirk, G Powell, et al.
FEMS Microbiology Immunology|December 1, 1991
Recombinant Trypanosoma cruzi antigens and Chagas' disease diagnosis: analysis of a workshopM J Levin, J Franco da Silveira, A C Frasch, et al.
The New England Journal of Medicine|December 8, 1991
A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndromeJ Falloon, J Kovacs, W Hughes, et al.
Memorias Do Instituto Oswaldo Cruz|October 1, 1990
Autoantibodies in Chagas' heart disease: possible markers of severe Chagas' heart complaintM J Levin, G Levitus, N Kerner, et al.
FEMS Immunology and Medical Microbiology|December 1, 1995
Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infectionC Aznar, P Lopez-Bergami, S Brandariz, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavirG L Drusano, D Z D'Argenio, S L Preston, et al.
AIDS (London, England)|December 2, 1998
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical TeamM S Saag, A Sonnerborg, R A Torres, et al.
Immunology Letters|January 1, 1992
The 70-kDa heat-shock protein is a major antigenic determinant in human Trypanosoma cruzi/Leishmania braziliensis braziliensis mixed infectionP Levy Yeyati, S Bonnefoy, G Mirkin, et al.
The Journal of Infectious Diseases|April 16, 1998
Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumoniaW T Hughes, E M Sillos, S LaFon, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|February 27, 1999
Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adultsP N Kumar, D E Sweet, J A McDowell, et al.
Clinical Therapeutics|December 1, 2001
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavirS Hetherington, S McGuirk, G Powell, et al.
FEMS Microbiology Immunology|December 1, 1991
Recombinant Trypanosoma cruzi antigens and Chagas' disease diagnosis: analysis of a workshopM J Levin, J Franco da Silveira, A C Frasch, et al.
The New England Journal of Medicine|December 8, 1991
A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndromeJ Falloon, J Kovacs, W Hughes, et al.
Memorias Do Instituto Oswaldo Cruz|October 1, 1990
Autoantibodies in Chagas' heart disease: possible markers of severe Chagas' heart complaintM J Levin, G Levitus, N Kerner, et al.
FEMS Immunology and Medical Microbiology|December 1, 1995
Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infectionC Aznar, P Lopez-Bergami, S Brandariz, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavirG L Drusano, D Z D'Argenio, S L Preston, et al.
AIDS (London, England)|December 2, 1998
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical TeamM S Saag, A Sonnerborg, R A Torres, et al.
Immunology Letters|January 1, 1992
The 70-kDa heat-shock protein is a major antigenic determinant in human Trypanosoma cruzi/Leishmania braziliensis braziliensis mixed infectionP Levy Yeyati, S Bonnefoy, G Mirkin, et al.
The Journal of Infectious Diseases|April 16, 1998
Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumoniaW T Hughes, E M Sillos, S LaFon, et al.
Pageof 4